Loading…

Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs

The differentiation-inducing effect of clinically applicable analogs of deoxyadenosine on myelomonocytic leukemia cells was examined. Monocytoid leukemia cells were more sensitive to the analogs than were erythroid or myeloid leukemia cells based on the inhibition of cell growth and induction of cel...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2000, Vol.24 (1), p.1-9
Main Authors: Niitsu, Nozomi, Umeda, Masanori, Honma, Yoshio
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c421t-a59c1fb06228c874feb4a46ed9aed4b31b078adf8985e771ee4539ec7ec3276a3
cites cdi_FETCH-LOGICAL-c421t-a59c1fb06228c874feb4a46ed9aed4b31b078adf8985e771ee4539ec7ec3276a3
container_end_page 9
container_issue 1
container_start_page 1
container_title Leukemia research
container_volume 24
creator Niitsu, Nozomi
Umeda, Masanori
Honma, Yoshio
description The differentiation-inducing effect of clinically applicable analogs of deoxyadenosine on myelomonocytic leukemia cells was examined. Monocytoid leukemia cells were more sensitive to the analogs than were erythroid or myeloid leukemia cells based on the inhibition of cell growth and induction of cell differentiation. Monocytoid leukemia cells were highly sensitive to combined treatment with 2′-deoxycoformycin (dCF) and 9-β- d-arabinofuranosyladenine (Ara A) for inducing cell differentiation. Ara A induced the differentiation of monocytoid leukemia U937 and THP-1 cells at concentrations which were 1/1000–10 000 of that at which it induced the differentiation of other cell lines in the presence of dCF. In combination with a low concentration of 1α,25-dihydroxyvitamin D 3 (VD 3), the induction of the monocytic differentiation was greater in monoblastic U937 cells. Adenosine deaminase-resistant analogs such as fludarabine (FLU) and cladribine (CdA) also induced the differentiation of human myelomonocytic leukemia cells, and these analogs synergistically enhanced the differentiation induced by all- trans retinoic acid (ATRA) or VD 3. CdA was the most potent analog for inducing the differentiation of myeloid leukemia NB4 and HL-60 cells in the presence or absence of ATRA. These findings indicate that dCF+Ara A and CdA may be effective for the therapy of acute monocytoid and myeloid leukemia, respectively.
doi_str_mv 10.1016/S0145-2126(99)00143-5
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17427996</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0145212699001435</els_id><sourcerecordid>17427996</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-a59c1fb06228c874feb4a46ed9aed4b31b078adf8985e771ee4539ec7ec3276a3</originalsourceid><addsrcrecordid>eNqFkM1u1TAQRi0EoreFRwB5gVBZBOzETuJVhSr-pCIWwNqa2ONiSOxiO1dkxauT9F5Rdqzs0ZzxNz6EPOHsJWe8ffWZcSGrmtftuVIv2Fo1lbxHdrzv1kvfyPtk9xc5Iac5f2eMScXVQ3LCWduItlE78vvjgmP0lkKwdIohmqVs5YjzD5w8UIPjmOk32CO13jlMGArNGLIvfu_LQku8a3goPobKBzsbH64pmCMUHbUYfy1gMcTsA655MMbr_Ig8cDBmfHw8z8jXt2--XL6vrj69-3D5-qoyoualAqkMdwNr67o3fSccDgJEi1YBWjE0fGBdD9b1qpfYdRxRyEah6dA0dddCc0aeH969SfHnjLnoyeftbxAwzlnzTtSdUu0KygNoUsw5odM3yU-QFs2Z3szrW_N606qV0rfmtVznnh4D5mFC-8_UQfUKPDsCkA2MLkEwPt9xtWBCbtjFAcPVxt5j0tl4DAatT2iKttH_Z5M_DWyjwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17427996</pqid></control><display><type>article</type><title>Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Niitsu, Nozomi ; Umeda, Masanori ; Honma, Yoshio</creator><creatorcontrib>Niitsu, Nozomi ; Umeda, Masanori ; Honma, Yoshio</creatorcontrib><description>The differentiation-inducing effect of clinically applicable analogs of deoxyadenosine on myelomonocytic leukemia cells was examined. Monocytoid leukemia cells were more sensitive to the analogs than were erythroid or myeloid leukemia cells based on the inhibition of cell growth and induction of cell differentiation. Monocytoid leukemia cells were highly sensitive to combined treatment with 2′-deoxycoformycin (dCF) and 9-β- d-arabinofuranosyladenine (Ara A) for inducing cell differentiation. Ara A induced the differentiation of monocytoid leukemia U937 and THP-1 cells at concentrations which were 1/1000–10 000 of that at which it induced the differentiation of other cell lines in the presence of dCF. In combination with a low concentration of 1α,25-dihydroxyvitamin D 3 (VD 3), the induction of the monocytic differentiation was greater in monoblastic U937 cells. Adenosine deaminase-resistant analogs such as fludarabine (FLU) and cladribine (CdA) also induced the differentiation of human myelomonocytic leukemia cells, and these analogs synergistically enhanced the differentiation induced by all- trans retinoic acid (ATRA) or VD 3. CdA was the most potent analog for inducing the differentiation of myeloid leukemia NB4 and HL-60 cells in the presence or absence of ATRA. These findings indicate that dCF+Ara A and CdA may be effective for the therapy of acute monocytoid and myeloid leukemia, respectively.</description><identifier>ISSN: 0145-2126</identifier><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/S0145-2126(99)00143-5</identifier><identifier>PMID: 10634639</identifier><identifier>CODEN: LEREDD</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>2'-deoxycoformycin ; 9-^b-D-^Aarabinofuranosyladenine ; Acute Disease ; Adenosine Deaminase Inhibitors ; Antimetabolites, Antineoplastic - pharmacology ; Antineoplastic agents ; Ara A ; Biological and medical sciences ; Calcitriol - pharmacology ; Cell Differentiation - drug effects ; Chemotherapy ; Cladribine ; Cladribine - pharmacology ; Deoxyadenosines - pharmacology ; Differentiation ; Dose-Response Relationship, Drug ; Drug Synergism ; Enzyme Inhibitors - pharmacology ; Fludarabine ; Hematologic and hematopoietic diseases ; HL-60 Cells - drug effects ; Human myelomonocytic leukemia ; Humans ; K562 Cells - drug effects ; Leukemia, Myeloid - drug therapy ; Leukemia, Myeloid - pathology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences ; Monocytes - drug effects ; Neoplasm Proteins - antagonists &amp; inhibitors ; Neoplastic Stem Cells - drug effects ; Pentostatin - pharmacology ; Pharmacology. Drug treatments ; Tretinoin - pharmacology ; Tumor Cells, Cultured - drug effects ; U937 Cells - drug effects ; Vidarabine - analogs &amp; derivatives ; Vidarabine - pharmacology</subject><ispartof>Leukemia research, 2000, Vol.24 (1), p.1-9</ispartof><rights>2000 Elsevier Science Ltd</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-a59c1fb06228c874feb4a46ed9aed4b31b078adf8985e771ee4539ec7ec3276a3</citedby><cites>FETCH-LOGICAL-c421t-a59c1fb06228c874feb4a46ed9aed4b31b078adf8985e771ee4539ec7ec3276a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1240459$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10634639$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niitsu, Nozomi</creatorcontrib><creatorcontrib>Umeda, Masanori</creatorcontrib><creatorcontrib>Honma, Yoshio</creatorcontrib><title>Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><description>The differentiation-inducing effect of clinically applicable analogs of deoxyadenosine on myelomonocytic leukemia cells was examined. Monocytoid leukemia cells were more sensitive to the analogs than were erythroid or myeloid leukemia cells based on the inhibition of cell growth and induction of cell differentiation. Monocytoid leukemia cells were highly sensitive to combined treatment with 2′-deoxycoformycin (dCF) and 9-β- d-arabinofuranosyladenine (Ara A) for inducing cell differentiation. Ara A induced the differentiation of monocytoid leukemia U937 and THP-1 cells at concentrations which were 1/1000–10 000 of that at which it induced the differentiation of other cell lines in the presence of dCF. In combination with a low concentration of 1α,25-dihydroxyvitamin D 3 (VD 3), the induction of the monocytic differentiation was greater in monoblastic U937 cells. Adenosine deaminase-resistant analogs such as fludarabine (FLU) and cladribine (CdA) also induced the differentiation of human myelomonocytic leukemia cells, and these analogs synergistically enhanced the differentiation induced by all- trans retinoic acid (ATRA) or VD 3. CdA was the most potent analog for inducing the differentiation of myeloid leukemia NB4 and HL-60 cells in the presence or absence of ATRA. These findings indicate that dCF+Ara A and CdA may be effective for the therapy of acute monocytoid and myeloid leukemia, respectively.</description><subject>2'-deoxycoformycin</subject><subject>9-^b-D-^Aarabinofuranosyladenine</subject><subject>Acute Disease</subject><subject>Adenosine Deaminase Inhibitors</subject><subject>Antimetabolites, Antineoplastic - pharmacology</subject><subject>Antineoplastic agents</subject><subject>Ara A</subject><subject>Biological and medical sciences</subject><subject>Calcitriol - pharmacology</subject><subject>Cell Differentiation - drug effects</subject><subject>Chemotherapy</subject><subject>Cladribine</subject><subject>Cladribine - pharmacology</subject><subject>Deoxyadenosines - pharmacology</subject><subject>Differentiation</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Synergism</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Fludarabine</subject><subject>Hematologic and hematopoietic diseases</subject><subject>HL-60 Cells - drug effects</subject><subject>Human myelomonocytic leukemia</subject><subject>Humans</subject><subject>K562 Cells - drug effects</subject><subject>Leukemia, Myeloid - drug therapy</subject><subject>Leukemia, Myeloid - pathology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><subject>Monocytes - drug effects</subject><subject>Neoplasm Proteins - antagonists &amp; inhibitors</subject><subject>Neoplastic Stem Cells - drug effects</subject><subject>Pentostatin - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Tretinoin - pharmacology</subject><subject>Tumor Cells, Cultured - drug effects</subject><subject>U937 Cells - drug effects</subject><subject>Vidarabine - analogs &amp; derivatives</subject><subject>Vidarabine - pharmacology</subject><issn>0145-2126</issn><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNqFkM1u1TAQRi0EoreFRwB5gVBZBOzETuJVhSr-pCIWwNqa2ONiSOxiO1dkxauT9F5Rdqzs0ZzxNz6EPOHsJWe8ffWZcSGrmtftuVIv2Fo1lbxHdrzv1kvfyPtk9xc5Iac5f2eMScXVQ3LCWduItlE78vvjgmP0lkKwdIohmqVs5YjzD5w8UIPjmOk32CO13jlMGArNGLIvfu_LQku8a3goPobKBzsbH64pmCMUHbUYfy1gMcTsA655MMbr_Ig8cDBmfHw8z8jXt2--XL6vrj69-3D5-qoyoualAqkMdwNr67o3fSccDgJEi1YBWjE0fGBdD9b1qpfYdRxRyEah6dA0dddCc0aeH969SfHnjLnoyeftbxAwzlnzTtSdUu0KygNoUsw5odM3yU-QFs2Z3szrW_N606qV0rfmtVznnh4D5mFC-8_UQfUKPDsCkA2MLkEwPt9xtWBCbtjFAcPVxt5j0tl4DAatT2iKttH_Z5M_DWyjwA</recordid><startdate>2000</startdate><enddate>2000</enddate><creator>Niitsu, Nozomi</creator><creator>Umeda, Masanori</creator><creator>Honma, Yoshio</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>2000</creationdate><title>Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs</title><author>Niitsu, Nozomi ; Umeda, Masanori ; Honma, Yoshio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-a59c1fb06228c874feb4a46ed9aed4b31b078adf8985e771ee4539ec7ec3276a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>2'-deoxycoformycin</topic><topic>9-^b-D-^Aarabinofuranosyladenine</topic><topic>Acute Disease</topic><topic>Adenosine Deaminase Inhibitors</topic><topic>Antimetabolites, Antineoplastic - pharmacology</topic><topic>Antineoplastic agents</topic><topic>Ara A</topic><topic>Biological and medical sciences</topic><topic>Calcitriol - pharmacology</topic><topic>Cell Differentiation - drug effects</topic><topic>Chemotherapy</topic><topic>Cladribine</topic><topic>Cladribine - pharmacology</topic><topic>Deoxyadenosines - pharmacology</topic><topic>Differentiation</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Synergism</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Fludarabine</topic><topic>Hematologic and hematopoietic diseases</topic><topic>HL-60 Cells - drug effects</topic><topic>Human myelomonocytic leukemia</topic><topic>Humans</topic><topic>K562 Cells - drug effects</topic><topic>Leukemia, Myeloid - drug therapy</topic><topic>Leukemia, Myeloid - pathology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><topic>Monocytes - drug effects</topic><topic>Neoplasm Proteins - antagonists &amp; inhibitors</topic><topic>Neoplastic Stem Cells - drug effects</topic><topic>Pentostatin - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Tretinoin - pharmacology</topic><topic>Tumor Cells, Cultured - drug effects</topic><topic>U937 Cells - drug effects</topic><topic>Vidarabine - analogs &amp; derivatives</topic><topic>Vidarabine - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niitsu, Nozomi</creatorcontrib><creatorcontrib>Umeda, Masanori</creatorcontrib><creatorcontrib>Honma, Yoshio</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niitsu, Nozomi</au><au>Umeda, Masanori</au><au>Honma, Yoshio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>2000</date><risdate>2000</risdate><volume>24</volume><issue>1</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>0145-2126</issn><eissn>1873-5835</eissn><coden>LEREDD</coden><abstract>The differentiation-inducing effect of clinically applicable analogs of deoxyadenosine on myelomonocytic leukemia cells was examined. Monocytoid leukemia cells were more sensitive to the analogs than were erythroid or myeloid leukemia cells based on the inhibition of cell growth and induction of cell differentiation. Monocytoid leukemia cells were highly sensitive to combined treatment with 2′-deoxycoformycin (dCF) and 9-β- d-arabinofuranosyladenine (Ara A) for inducing cell differentiation. Ara A induced the differentiation of monocytoid leukemia U937 and THP-1 cells at concentrations which were 1/1000–10 000 of that at which it induced the differentiation of other cell lines in the presence of dCF. In combination with a low concentration of 1α,25-dihydroxyvitamin D 3 (VD 3), the induction of the monocytic differentiation was greater in monoblastic U937 cells. Adenosine deaminase-resistant analogs such as fludarabine (FLU) and cladribine (CdA) also induced the differentiation of human myelomonocytic leukemia cells, and these analogs synergistically enhanced the differentiation induced by all- trans retinoic acid (ATRA) or VD 3. CdA was the most potent analog for inducing the differentiation of myeloid leukemia NB4 and HL-60 cells in the presence or absence of ATRA. These findings indicate that dCF+Ara A and CdA may be effective for the therapy of acute monocytoid and myeloid leukemia, respectively.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>10634639</pmid><doi>10.1016/S0145-2126(99)00143-5</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0145-2126
ispartof Leukemia research, 2000, Vol.24 (1), p.1-9
issn 0145-2126
1873-5835
language eng
recordid cdi_proquest_miscellaneous_17427996
source ScienceDirect Freedom Collection 2022-2024
subjects 2'-deoxycoformycin
9-^b-D-^Aarabinofuranosyladenine
Acute Disease
Adenosine Deaminase Inhibitors
Antimetabolites, Antineoplastic - pharmacology
Antineoplastic agents
Ara A
Biological and medical sciences
Calcitriol - pharmacology
Cell Differentiation - drug effects
Chemotherapy
Cladribine
Cladribine - pharmacology
Deoxyadenosines - pharmacology
Differentiation
Dose-Response Relationship, Drug
Drug Synergism
Enzyme Inhibitors - pharmacology
Fludarabine
Hematologic and hematopoietic diseases
HL-60 Cells - drug effects
Human myelomonocytic leukemia
Humans
K562 Cells - drug effects
Leukemia, Myeloid - drug therapy
Leukemia, Myeloid - pathology
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
Monocytes - drug effects
Neoplasm Proteins - antagonists & inhibitors
Neoplastic Stem Cells - drug effects
Pentostatin - pharmacology
Pharmacology. Drug treatments
Tretinoin - pharmacology
Tumor Cells, Cultured - drug effects
U937 Cells - drug effects
Vidarabine - analogs & derivatives
Vidarabine - pharmacology
title Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A49%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Myeloid%20and%20monocytoid%20leukemia%20cells%20have%20different%20sensitivity%20to%20differentiation-inducing%20activity%20of%20deoxyadenosine%20analogs&rft.jtitle=Leukemia%20research&rft.au=Niitsu,%20Nozomi&rft.date=2000&rft.volume=24&rft.issue=1&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=0145-2126&rft.eissn=1873-5835&rft.coden=LEREDD&rft_id=info:doi/10.1016/S0145-2126(99)00143-5&rft_dat=%3Cproquest_cross%3E17427996%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c421t-a59c1fb06228c874feb4a46ed9aed4b31b078adf8985e771ee4539ec7ec3276a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17427996&rft_id=info:pmid/10634639&rfr_iscdi=true